1. CAR-T cells targeting HER2, ICAM-1, etc., show significant efficacy in GC.2. Novel CAR-T approaches like CDH17CART effectively treat gastrointestinal tumors.3. CLDN18.2-specific CAR-T cells demonstrate robust tumor elimination with favorable safety. Here, ERBB2 is linked to digestive system neoplasm.